Removing EPO signaling in mouse liver tumors leads to tumor regression along with sensitivity to immunotherapy.

Removing EPO signaling in mouse liver tumors leads to tumor regression along with sensitivity to immunotherapy.

The data, presented in a poster titled "AP402, a bispecific antibody targeting p95HER2 and CD137, shows potent antitumor activity," highlight the therapeutic potential of AP402 to address ...

A Ludwig Cancer Research study has identified a specific mode of fat uptake by immune cells within tumors that serves as a ...

From a meeting that celebrates basic research and being "first," a look at 3 data sets on therapies that would break new ...

Many different cancer treatments work to directly target the tumor or the cells around it. The immediate goal is to mitigate ...

LIfT BioSciences announces partnership with University of Galway for clinical trial in Ireland ...

Runimotamab plus trastuzumab resulted in positive clinical activity and tolerability over runimotamab alone in patients with ...

SENTI-202, a CAR NK cell therapy, achieved complete remission ... causing collateral autoimmune disease or affecting antitumor T cells,” said Douglas Adkins, MD, professor of medicine and ...

Updated findings from a phase 2 study investigating the IL-2–binding monoclonal antibody AU-007 show a manageable safety ...